ADAR and B-cell non-Hodgkin lymphoma: We also assess the role of ADAR1-mediated MAVS editing in mediating inflammation through the induction of IFN/NF-κΒ, and find that a lower level of ADAR1 or MAVS in B cell lymphoma does not correlate with an increase of IFN response as observed for solid tumors (such as lung adenocarcinoma or pancreatic cancer29).